Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Fulcrum Therapeutics, Inc. has received a consensus rating of "Buy" from analysts, with an average twelve-month target price of $9.60.
• Recently, Leerink Partners upgraded Fulcrum's rating to "outperform" and increased their price objective from $4.00 to $12.00.
• Institutional investors own approximately 89.83% of Fulcrum's shares, with significant recent stakes acquired by firms like Adage Capital Partners.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has been given a consensus recommendation of "Buy" by the six analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $9.60.

Several research analysts have commented on the company. HC Wainwright raised Fulcrum Therapeutics from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $4.00 to $12.00 in a research report on Tuesday, July 29th. Piper Sandler reaffirmed an "overweight" rating and issued a $9.00 price target (up from $6.00) on shares of Fulcrum Therapeutics in a research report on Thursday, May 29th. Leerink Partners upgraded Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and boosted their price objective for the company from $4.00 to $12.00 in a research report on Friday, May 23rd. Wall Street Zen cut Fulcrum Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Finally, Royal Bank Of Canada upped their price target on Fulcrum Therapeutics from $4.00 to $5.00 and gave the company a "sector perform" rating in a research report on Wednesday, July 30th.

Fulcrum Therapeutics Stock Down 2.0%

FULC stock traded down $0.15 during midday trading on Tuesday, hitting $7.39. 2,098,632 shares of the company traded hands, compared to its average volume of 372,330. Fulcrum Therapeutics has a twelve month low of $2.32 and a twelve month high of $8.50. The business has a 50 day simple moving average of $7.04 and a 200-day simple moving average of $5.72. The stock has a market capitalization of $399.73 million, a price-to-earnings ratio of -6.06 and a beta of 2.82.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.01. Equities research analysts forecast that Fulcrum Therapeutics will post -0.16 EPS for the current year.

Institutional Trading of Fulcrum Therapeutics

Large investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets bought a new stake in Fulcrum Therapeutics in the fourth quarter valued at $38,000. Russell Investments Group Ltd. grew its holdings in shares of Fulcrum Therapeutics by 4,209.3% during the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company's stock worth $64,000 after purchasing an additional 9,092 shares during the last quarter. Jump Financial LLC bought a new stake in shares of Fulcrum Therapeutics during the first quarter worth $30,000. Brooklyn Investment Group grew its holdings in shares of Fulcrum Therapeutics by 209.7% during the first quarter. Brooklyn Investment Group now owns 12,190 shares of the company's stock worth $35,000 after purchasing an additional 8,254 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of Fulcrum Therapeutics by 26.1% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 12,943 shares of the company's stock worth $89,000 after purchasing an additional 2,677 shares during the last quarter. 89.83% of the stock is currently owned by institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.